Cargando…

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

BACKGROUND: Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic p...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Sten, Mischak, Harald, Zürbig, Petra, Parving, Hans-Henrik, Rossing, Peter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988775/
https://www.ncbi.nlm.nih.gov/pubmed/21040538
http://dx.doi.org/10.1186/1471-2369-11-29
_version_ 1782192278604873728
author Andersen, Sten
Mischak, Harald
Zürbig, Petra
Parving, Hans-Henrik
Rossing, Peter
author_facet Andersen, Sten
Mischak, Harald
Zürbig, Petra
Parving, Hans-Henrik
Rossing, Peter
author_sort Andersen, Sten
collection PubMed
description BACKGROUND: Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome. METHODS: High-resolution capillary-electrophoresis coupled to mass-spectrometry (CE-MS) was used to profile the low-molecular-weight proteome in urine of a subgroup of patients from a two year randomized irbesartan versus placebo therapy trial, which included hypertensive type 2 diabetic patients with microalbuminuria on ongoing antihypertensive medication (IRMA2-substudy). RESULTS: We demonstrate that the therapy with 300 mg Irbesartan daily over a period of two years results in significant changes of the urinary proteome. Both, a classifier developed previously that consists of urinary peptides indicative of chronic kidney disease, as well as several individual peptides changed significantly after treatment. These changes were not observed in the placebo-treated individuals. Most prominent are changes of urinary collagen fragments associated with progression of diabetic nephropathy, indicating normalization in urinary peptides. CONCLUSION: CE-MS analysis of urine enabled identification of peptides as potential surrogate markers for renoprotection in microalbuminuric type 2 diabetic patients, which show persistent improvement after longterm treatment with Irbesartan. The results suggest that a major benefit of treatment by Irbesartan may be improvement of collagen turnover, reduction of fibrosis. They further suggest that urinary proteome analysis could be utilized to assess potential benefit of therapeutic intervention, providing statistically significant results even on a small population.
format Text
id pubmed-2988775
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29887752010-11-20 Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria Andersen, Sten Mischak, Harald Zürbig, Petra Parving, Hans-Henrik Rossing, Peter BMC Nephrol Research Article BACKGROUND: Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome. METHODS: High-resolution capillary-electrophoresis coupled to mass-spectrometry (CE-MS) was used to profile the low-molecular-weight proteome in urine of a subgroup of patients from a two year randomized irbesartan versus placebo therapy trial, which included hypertensive type 2 diabetic patients with microalbuminuria on ongoing antihypertensive medication (IRMA2-substudy). RESULTS: We demonstrate that the therapy with 300 mg Irbesartan daily over a period of two years results in significant changes of the urinary proteome. Both, a classifier developed previously that consists of urinary peptides indicative of chronic kidney disease, as well as several individual peptides changed significantly after treatment. These changes were not observed in the placebo-treated individuals. Most prominent are changes of urinary collagen fragments associated with progression of diabetic nephropathy, indicating normalization in urinary peptides. CONCLUSION: CE-MS analysis of urine enabled identification of peptides as potential surrogate markers for renoprotection in microalbuminuric type 2 diabetic patients, which show persistent improvement after longterm treatment with Irbesartan. The results suggest that a major benefit of treatment by Irbesartan may be improvement of collagen turnover, reduction of fibrosis. They further suggest that urinary proteome analysis could be utilized to assess potential benefit of therapeutic intervention, providing statistically significant results even on a small population. BioMed Central 2010-11-01 /pmc/articles/PMC2988775/ /pubmed/21040538 http://dx.doi.org/10.1186/1471-2369-11-29 Text en Copyright ©2010 Andersen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Andersen, Sten
Mischak, Harald
Zürbig, Petra
Parving, Hans-Henrik
Rossing, Peter
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
title Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
title_full Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
title_fullStr Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
title_full_unstemmed Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
title_short Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
title_sort urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988775/
https://www.ncbi.nlm.nih.gov/pubmed/21040538
http://dx.doi.org/10.1186/1471-2369-11-29
work_keys_str_mv AT andersensten urinaryproteomeanalysisenablesassessmentofrenoprotectivetreatmentintype2diabeticpatientswithmicroalbuminuria
AT mischakharald urinaryproteomeanalysisenablesassessmentofrenoprotectivetreatmentintype2diabeticpatientswithmicroalbuminuria
AT zurbigpetra urinaryproteomeanalysisenablesassessmentofrenoprotectivetreatmentintype2diabeticpatientswithmicroalbuminuria
AT parvinghanshenrik urinaryproteomeanalysisenablesassessmentofrenoprotectivetreatmentintype2diabeticpatientswithmicroalbuminuria
AT rossingpeter urinaryproteomeanalysisenablesassessmentofrenoprotectivetreatmentintype2diabeticpatientswithmicroalbuminuria